Literature DB >> 8943813

The frequency and mechanism of loss of heterozygosity on chromosome 11q in breast cancer.

I P Tomlinson1, H Nicolai, E Solomon, W F Bodmer.   

Abstract

Loss of heterozygosity (LOH, allele loss) occurs frequently on the long arm of chromosome 11 in breast cancer. Seventy-one paired tumour/normal DNA samples from breast cancer patients under 50 years old were studied for allele loss at four microsatellite loci on 11q: D11S29 (11q23.3), NCAM (11q22-q23), D11S968 (11qtel), and D11S1313 (11qcen). The maximum frequency of LOH (approximately 35 per cent) was found at the D11S29 and NCAM loci. This result is consistent with previous studies and the frequency of allele loss is moderate to high compared with the usual baseline of 0-20 per cent. In most of the cases studied, LOH on chromosome 11q could be accounted for by one of two mechanisms. Either chromosomal non-disjunction had occurred, or sequences stretching from the telomere at least as far as NCAM had undergone deletion or mitotic recombination. These results suggest that a putative tumour suppressor gene is most likely to exist near 11q22-q23. There was a very low frequency of microsatellite instability in the tumours. An association was found between lack of progesterone receptor (PgR) expression and LOH at NCAM, suggesting that deletion of sequences on 11q may prevent high levels of PgR expression in some cases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8943813     DOI: 10.1002/(SICI)1096-9896(199609)180:1<38::AID-PATH638>3.0.CO;2-C

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  11 in total

Review 1.  The loss of estrogen and progesterone receptor gene expression in human breast cancer.

Authors:  R G Lapidus; S J Nass; N E Davidson
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-01       Impact factor: 2.673

2.  LARG at chromosome 11q23 has functional characteristics of a tumor suppressor in human breast and colorectal cancer.

Authors:  D C T Ong; Y M Ho; C Rudduck; K Chin; W-L Kuo; D K H Lie; C L M Chua; P H Tan; K W Eu; F Seow-Choen; C Y Wong; G S Hong; J W Gray; A S G Lee
Journal:  Oncogene       Date:  2009-09-07       Impact factor: 9.867

3.  Differential patterns of allelic loss in estrogen receptor-positive infiltrating lobular and ductal breast cancer.

Authors:  L W M Loo; C Ton; Y-W Wang; D I Grove; H Bouzek; N Vartanian; M-G Lin; X Yuan; T L Lawton; J R Daling; K E Malone; C I Li; L Hsu; P L Porter
Journal:  Genes Chromosomes Cancer       Date:  2008-12       Impact factor: 5.006

4.  Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women.

Authors:  R L Balleine; M J Earl; M L Greenberg; C L Clarke
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

5.  Improved relapse-free survival on aromatase inhibitors in breast cancer is associated with interaction between oestrogen receptor-α and progesterone receptor-b.

Authors:  Cameron E Snell; Madeline Gough; Cheng Liu; Kathryn Middleton; Christopher Pyke; Catherine Shannon; Natasha Woodward; Theresa E Hickey; Jane E Armes; Wayne D Tilley
Journal:  Br J Cancer       Date:  2018-11-09       Impact factor: 7.640

Review 6.  Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications.

Authors:  Emma Zattarin; Rita Leporati; Francesca Ligorio; Riccardo Lobefaro; Andrea Vingiani; Giancarlo Pruneri; Claudio Vernieri
Journal:  Cells       Date:  2020-12-09       Impact factor: 6.600

7.  The role of microsatellite instability at chromosome 11p15.5 in the progression of breast ductal carcinoma.

Authors:  Dong-Ja Kim; Ji-Young Park; Myung-Hoon Lee; Yoon-Kyung Sohn
Journal:  J Korean Med Sci       Date:  2004-10       Impact factor: 2.153

8.  Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response.

Authors:  Sophie Lehn; Nicholas P Tobin; Andrew H Sims; Olle Stål; Karin Jirström; Håkan Axelson; Göran Landberg
Journal:  BMC Cancer       Date:  2014-02-22       Impact factor: 4.430

9.  Progesterone receptor modulates ERα action in breast cancer.

Authors:  Hisham Mohammed; I Alasdair Russell; Rory Stark; Oscar M Rueda; Theresa E Hickey; Gerard A Tarulli; Aurelien A Serandour; Aurelien A A Serandour; Stephen N Birrell; Alejandra Bruna; Amel Saadi; Suraj Menon; James Hadfield; Michelle Pugh; Ganesh V Raj; Gordon D Brown; Clive D'Santos; Jessica L L Robinson; Grace Silva; Rosalind Launchbury; Charles M Perou; John Stingl; Carlos Caldas; Wayne D Tilley; Jason S Carroll
Journal:  Nature       Date:  2015-07-08       Impact factor: 49.962

10.  Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer.

Authors:  Hari Singhal; Marianne E Greene; Gerard Tarulli; Allison L Zarnke; Ryan J Bourgo; Muriel Laine; Ya-Fang Chang; Shihong Ma; Anna G Dembo; Ganesh V Raj; Theresa E Hickey; Wayne D Tilley; Geoffrey L Greene
Journal:  Sci Adv       Date:  2016-06-24       Impact factor: 14.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.